Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

glioma-associated antigen peptide-pulsed autologous dendritic cell vaccine

A cancer vaccine comprised of autologous dendritic cells pulsed with synthetic glioma-associated antigen (GAA) peptides with potential antineoplastic activity. Upon administration, this vaccine may stimulate anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against GAA peptide-expressing glioma cells, resulting in tumor cell lysis.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Abbreviation:	GAA peptide-pulsed autologous dendritic cell vaccine

glioma-associated antigen peptide-pulsed autologous dendritic cell vaccine

Search NCI's Drug Dictionary